Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Rhea-AI Summary

Cyclerion Therapeutics (Nasdaq: CYCN) and Beacon Biosignals have expanded their strategic partnership to enhance the development of Cyclerion's therapeutics targeting neurological diseases linked to cognitive impairment. Utilizing Beacon's EEG neurobiomarker platform, the collaboration aims to identify biomarkers for better patient selection and clinical endpoints. Cyclerion’s lead candidate, CY6463, has shown promising impacts on EEG parameters and is being evaluated in various ongoing studies, including those for Alzheimer's disease and schizophrenia.

Positive

• Expanded partnership with Beacon Biosignals to enhance clinical development.
• CY6463 shows favorable safety and tolerability in initial studies.
• Promising effects on EEG measures and neuroinflammation with CY6463.

Negative

• None.

BOSTON, July 8, 2021 /PRNewswire/ -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies.  This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion's investigational therapeutics for neurological diseases associated with cognitive impairment.

Beacon Biosignals' EEG neurobiomarker platform is engineered to discover and scale new clinical paradigms for patients with neurological and psychiatric disease. Beacon Biosignals brings a world-class clinical electroencephalogram (EEG) database coupled with proprietary, artificial intelligence-based algorithms and analytical capabilities to identify neurological biomarkers of drug action and efficacy. Distinct EEG profiles are associated with neurodevelopmental status and various neurological diseases, and can be affected by neurologically active therapeutics. The platform rapidly characterizes these effects and guides dose selection in humans to help overcome the challenges of translating PK/PD models from preclinical animal studies.

Beacon Biosignals and Cyclerion previously collaborated on the analysis of data from a Cyclerion clinical translational pharmacology study of CY6463 which demonstrated clear effects on EEG parameters associated with aging and disease. These data were recently presented at the annual meeting of the American Academy of Neurology (Glasser et al., 2021). Incorporation of the Beacon Biosignals approach in ongoing and planned Cyclerion patient studies is expected to support the continued clinical development of CY6463, the Company's lead clinical program, as well as CY3018, a next-generation preclinical program.

CY6463 is an oral, first-in-class, central nervous system (CNS)-penetrant sGC stimulator that is being developed for neurological diseases associated with cognitive impairment. CY6463 was designed to address multiple pathophysiological features of neurodegenerative and neuropsychiatric diseases associated with cognitive impairment. Results from initial CY6463 clinical studies have demonstrated favorable safety and tolerability and pharmacologically relevant drug exposure in the cerebral spinal fluid. In addition, CY6463 resulted in promising impacts on EEG measures, neuroinflammation, and other neurophysiological measures that support continued clinical development.

Patient studies to further evaluate CY6463 safety and signals of clinical activity in studies in Alzheimer's disease with vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) are ongoing, and a study in individuals with Cognitive Impairment Associated with Schizophrenia (CIAS) is expected to initiate shortly. Analysis of EEG and other neurological biomarkers will be an important aspect of these studies.

"Beacon Biosignals is the leader in the identification of disease-relevant EEG neurological biomarkers. We believe that the application of this technology to our innovative pipeline may be quite powerful in guiding efficient drug development, and we look forward to a productive partnership focused on successfully advancing CY6463 for diseases associated with cognitive impairment," said Andy Busch Ph.D., Chief Scientific Officer of Cyclerion Therapeutics.

"We are eager to apply our proprietary AI-based analytical capabilities to support the development of Cyclerion's promising therapeutic candidates. We believe that our platform has the capacity to identify novel disease-relevant biomarkers that may help guide patient selection or endpoint identification for future clinical development," said Jacob Donoghue, M.D., Ph.D., Chief Executive Officer of Beacon Biosignals.

About Cyclerion Therapeutics 
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463, has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS), and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next-generation sGC stimulator.

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

About Beacon Biosignals
Beacon's machine learning platform for EEG enables and accelerates new treatments that transform the lives of patients with neurological and psychiatric disease. Through novel machine learning algorithms, enormous datasets, and advances in software engineering, Beacon Biosignals is changing the way patients are treated for disorders of the brain.

For more information about Beacon Biosignals, please visit https://beacon.bio/ and follow us on Twitter (@biosignals) and LinkedIn (https://www.linkedin.com/company/beacon-biosignals).

Forward Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. We may, in some cases use terms such as "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "may," "could," "might," "likely," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks listed under the heading "Risk Factors" and elsewhere in Cyclerion's 2020 Form 10-K filed on February 25, 2021, and subsequent SEC filings including the Form 10-Q filed on April 30, 2021. Investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Cyclerion undertakes no obligation to update these forward-looking statements, except as required by law.

Cyclerion Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

Cyclerion Media
Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com 

Beacon Biosignals Media
Jacob Donoghue M.D., Ph.D.
jake@beacon.bio

 

View original content:https://www.prnewswire.com/news-releases/beacon-biosignals-and-cyclerion-therapeutics-announce-strategic-partnership-301328426.html

SOURCE Beacon Biosignals

FAQ

What is the partnership between CYCN and Beacon Biosignals about?

The partnership aims to identify disease-relevant biomarkers to improve patient selection and endpoints for Cyclerion's clinical development of therapies for cognitive impairment.

What are the key findings related to CY6463 in the press release?

Initial studies of CY6463 demonstrate favorable safety and efficacy, impacting EEG measures and neuroinflammation.

What diseases is CY6463 being developed for?

CY6463 is being developed for neurological diseases associated with cognitive impairment, including Alzheimer's disease and schizophrenia.

When can we expect results from ongoing CY6463 studies?

Ongoing studies are currently assessing CY6463's safety and signals of clinical activity, with results expected as the studies progress.